SILO PHARMA, INC. Proceeds from Collection of Notes Receivable
SILO PHARMA, INC. (SILO) reported Proceeds from Collection of Notes Receivable of $1.15 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromCollectionOfNotesReceivable · last filed 2024-08-13
- SILO PHARMA, INC. proceeds from collection of notes receivable for the quarter ending 2024-06-30 was $998.93K.
- SILO PHARMA, INC. proceeds from collection of notes receivable for the quarter ending 2024-03-31 was $150.39K.
- SILO PHARMA, INC. proceeds from collection of notes receivable for the quarter ending 2022-12-31 was $0.00.
- SILO PHARMA, INC. proceeds from collection of notes receivable for the quarter ending 2022-09-30 was $0.00.
- SILO PHARMA, INC. proceeds from collection of notes receivable for fiscal 2022 was $20.00K, a 166.67% increase from fiscal 2021.
- SILO PHARMA, INC. proceeds from collection of notes receivable for fiscal 2021 was $7.50K, a 80.77% decline from fiscal 2020.
- SILO PHARMA, INC. proceeds from collection of notes receivable for fiscal 2020 was $39.00K.
| Period end | Proceeds from Collection of Notes Receivable 3 month | Proceeds from Collection of Notes Receivable 3 month as first filed | Proceeds from Collection of Notes Receivable 6 month | Proceeds from Collection of Notes Receivable 9 month | Proceeds from Collection of Notes Receivable 12 month |
|---|---|---|---|---|---|
| 2024-06-30 | $998.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.15M 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $150.39K 10-Q · filed 2024-05-13 | ||||
| 2023-06-30 | $517.82K 10-Q · filed 2024-08-13 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $20.00K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $20.00K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $20.00K 10-Q · filed 2023-08-11 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$62.00K derived: sum of 2 quarters · filed 2023-03-24 | $0.00 derived: sum of 3 quarters · filed 2023-03-24 | $7.50K 10-K · filed 2023-03-24 | |
| 2021-09-30 | -$62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $7.50K 10-Q · filed 2022-11-10 | $26.50K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $69.50K 10-Q · filed 2021-08-13 | $88.50K derived: sum of 3 quarters · filed 2022-05-13 | $93.50K derived: sum of 4 quarters · filed 2022-05-13 | |
| 2021-03-31 | $7.50K 10-Q · filed 2022-05-13 | $23.50K 10-Q · filed 2021-05-17 | $26.50K derived: sum of 2 quarters · filed 2022-05-13 | $31.50K derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $19.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-17 | $24.00K derived: sum of 2 quarters · filed 2021-05-17 | $39.00K 10-K/A · filed 2021-05-17 | ||
| 2020-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $20.00K 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $15.00K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |